vs
ASP Isotopes Inc.（ASPI）与科迪华（CTVA）财务数据对比。点击上方公司名可切换其他公司
科迪华的季度营收约是ASP Isotopes Inc.的234.7倍（$3.9B vs $16.7M）。ASP Isotopes Inc.同比增速更快（1295.7% vs -1.7%）。科迪华自由现金流更多（$4.2B vs $-47.4M）。过去两年ASP Isotopes Inc.的营收复合增速更高（345.2% vs -6.7%）
ASP Isotopes Inc.是一家特种材料企业，专注于高纯度定制同位素的研发与生产，产品广泛应用于核医学、靶向抗癌治疗、清洁能源及工业研究等领域，客户覆盖北美、欧洲及亚太地区。
科迪华是一家美国农业科技企业，主营种子与作物保护产品，涵盖除草剂、杀虫剂、杀菌剂及生物制剂，业务覆盖全球110个国家，总部位于印第安纳州印第安纳波利斯，旗下大部分种子产品以先锋良种国际品牌销售。
ASPI vs CTVA — 直观对比
营收规模更大
CTVA
是对方的234.7倍
$16.7M
营收增速更快
ASPI
高出1297.4%
-1.7%
自由现金流更多
CTVA
多$4.2B
$-47.4M
两年增速更快
ASPI
近两年复合增速
-6.7%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $16.7M | $3.9B |
| 净利润 | — | $-552.0M |
| 毛利率 | 12.5% | 42.4% |
| 营业利润率 | — | -13.6% |
| 净利率 | — | -14.1% |
| 营收同比 | 1295.7% | -1.7% |
| 净利润同比 | -586.8% | -1246.3% |
| 每股收益（稀释后） | — | $-0.80 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASPICTVA
| Q4 25 | $16.7M | $3.9B | ||
| Q3 25 | $4.9M | $2.6B | ||
| Q2 25 | $1.2M | $6.5B | ||
| Q1 25 | $1.1M | $4.4B | ||
| Q4 24 | $1.2M | $4.0B | ||
| Q3 24 | $1.1M | $2.3B | ||
| Q2 24 | $1.0M | $6.1B | ||
| Q1 24 | $840.4K | $4.5B |
净利润ASPICTVA
| Q4 25 | — | $-552.0M | ||
| Q3 25 | $-12.9M | $-320.0M | ||
| Q2 25 | $-75.2M | $1.3B | ||
| Q1 25 | $-8.5M | $652.0M | ||
| Q4 24 | — | $-41.0M | ||
| Q3 24 | $-7.4M | $-524.0M | ||
| Q2 24 | $-8.9M | $1.1B | ||
| Q1 24 | $-7.0M | $419.0M |
毛利率ASPICTVA
| Q4 25 | 12.5% | 42.4% | ||
| Q3 25 | 8.7% | 37.2% | ||
| Q2 25 | 47.7% | 54.6% | ||
| Q1 25 | 29.7% | 47.0% | ||
| Q4 24 | 50.7% | 37.3% | ||
| Q3 24 | 27.0% | 32.7% | ||
| Q2 24 | 41.2% | 52.3% | ||
| Q1 24 | 33.2% | 43.2% |
营业利润率ASPICTVA
| Q4 25 | — | -13.6% | ||
| Q3 25 | -306.1% | -14.1% | ||
| Q2 25 | -998.8% | 27.9% | ||
| Q1 25 | -721.9% | 17.7% | ||
| Q4 24 | — | 2.2% | ||
| Q3 24 | -499.6% | -27.2% | ||
| Q2 24 | -729.5% | 21.9% | ||
| Q1 24 | -691.9% | 10.7% |
净利率ASPICTVA
| Q4 25 | — | -14.1% | ||
| Q3 25 | -263.7% | -12.2% | ||
| Q2 25 | -6271.7% | 20.4% | ||
| Q1 25 | -768.1% | 14.8% | ||
| Q4 24 | — | -1.0% | ||
| Q3 24 | -676.2% | -22.5% | ||
| Q2 24 | -868.8% | 17.2% | ||
| Q1 24 | -828.8% | 9.3% |
每股收益（稀释后）ASPICTVA
| Q4 25 | — | $-0.80 | ||
| Q3 25 | $-0.15 | $-0.47 | ||
| Q2 25 | $-1.03 | $1.92 | ||
| Q1 25 | $-0.12 | $0.95 | ||
| Q4 24 | — | $-0.05 | ||
| Q3 24 | $-0.12 | $-0.76 | ||
| Q2 24 | $-0.24 | $1.51 | ||
| Q1 24 | $-0.16 | $0.60 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $333.3M | $4.5B |
| 总债务越低越好 | $14.4M | $1.7B |
| 股东权益账面价值 | $204.2M | $24.1B |
| 总资产 | $498.0M | $42.8B |
| 负债/权益比越低杠杆越低 | 0.07× | 0.07× |
8季度趋势，按日历期对齐
现金及短期投资ASPICTVA
| Q4 25 | $333.3M | $4.5B | ||
| Q3 25 | $113.9M | $2.6B | ||
| Q2 25 | $67.7M | $2.1B | ||
| Q1 25 | $56.0M | $2.0B | ||
| Q4 24 | $61.9M | $3.2B | ||
| Q3 24 | $51.6M | $2.5B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $1.7B |
总债务ASPICTVA
| Q4 25 | $14.4M | $1.7B | ||
| Q3 25 | $13.9M | $1.7B | ||
| Q2 25 | — | $1.7B | ||
| Q1 25 | — | $1.8B | ||
| Q4 24 | $2.4M | $2.0B | ||
| Q3 24 | — | $2.0B | ||
| Q2 24 | — | $2.5B | ||
| Q1 24 | — | $2.5B |
股东权益ASPICTVA
| Q4 25 | $204.2M | $24.1B | ||
| Q3 25 | $74.1M | $25.2B | ||
| Q2 25 | $25.2M | $25.9B | ||
| Q1 25 | $42.5M | $24.3B | ||
| Q4 24 | $47.9M | $23.8B | ||
| Q3 24 | $38.7M | $24.7B | ||
| Q2 24 | $11.0M | $25.2B | ||
| Q1 24 | $10.5M | $24.8B |
总资产ASPICTVA
| Q4 25 | $498.0M | $42.8B | ||
| Q3 25 | $225.9M | $42.2B | ||
| Q2 25 | $135.9M | $41.8B | ||
| Q1 25 | $90.9M | $42.1B | ||
| Q4 24 | $94.3M | $40.8B | ||
| Q3 24 | $84.1M | $41.9B | ||
| Q2 24 | $54.8M | $41.5B | ||
| Q1 24 | $45.4M | $43.6B |
负债/权益比ASPICTVA
| Q4 25 | 0.07× | 0.07× | ||
| Q3 25 | 0.19× | 0.07× | ||
| Q2 25 | — | 0.07× | ||
| Q1 25 | — | 0.07× | ||
| Q4 24 | 0.05× | 0.08× | ||
| Q3 24 | — | 0.08× | ||
| Q2 24 | — | 0.10× | ||
| Q1 24 | — | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-37.8M | $4.4B |
| 自由现金流经营现金流 - 资本支出 | $-47.4M | $4.2B |
| 自由现金流率自由现金流/营收 | -284.7% | 106.2% |
| 资本支出强度资本支出/营收 | 57.9% | 5.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-74.6M | $2.8B |
8季度趋势，按日历期对齐
经营现金流ASPICTVA
| Q4 25 | $-37.8M | $4.4B | ||
| Q3 25 | $-8.9M | $193.0M | ||
| Q2 25 | $-7.9M | $947.0M | ||
| Q1 25 | $-3.2M | $-2.1B | ||
| Q4 24 | $-16.7M | $4.2B | ||
| Q3 24 | $-4.8M | $130.0M | ||
| Q2 24 | $-5.1M | $451.0M | ||
| Q1 24 | $-3.0M | $-2.6B |
自由现金流ASPICTVA
| Q4 25 | $-47.4M | $4.2B | ||
| Q3 25 | $-12.0M | $36.0M | ||
| Q2 25 | $-9.7M | $829.0M | ||
| Q1 25 | $-5.5M | $-2.2B | ||
| Q4 24 | $-26.4M | $4.0B | ||
| Q3 24 | $-9.3M | $-24.0M | ||
| Q2 24 | $-7.7M | $337.0M | ||
| Q1 24 | $-4.2M | $-2.8B |
自由现金流率ASPICTVA
| Q4 25 | -284.7% | 106.2% | ||
| Q3 25 | -245.5% | 1.4% | ||
| Q2 25 | -809.4% | 12.8% | ||
| Q1 25 | -497.4% | -49.9% | ||
| Q4 24 | -2209.3% | 100.4% | ||
| Q3 24 | -857.3% | -1.0% | ||
| Q2 24 | -757.8% | 5.5% | ||
| Q1 24 | -501.7% | -61.4% |
资本支出强度ASPICTVA
| Q4 25 | 57.9% | 5.7% | ||
| Q3 25 | 64.4% | 6.0% | ||
| Q2 25 | 150.1% | 1.8% | ||
| Q1 25 | 209.6% | 2.1% | ||
| Q4 24 | 810.5% | 4.6% | ||
| Q3 24 | 412.3% | 6.6% | ||
| Q2 24 | 256.5% | 1.9% | ||
| Q1 24 | 148.3% | 3.3% |
现金转化率ASPICTVA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.72× | ||
| Q1 25 | — | -3.23× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.43× | ||
| Q1 24 | — | -6.23× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASPI
暂无分部数据
CTVA
| Corn | $1.4B | 35% |
| Herbicides | $1.1B | 27% |
| Insecticides | $488.0M | 12% |
| Fungicides | $272.0M | 7% |
| Biologicals | $191.0M | 5% |
| Soybean | $164.0M | 4% |
| Other | $160.0M | 4% |
| Otheroilseeds | $94.0M | 2% |
